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Abstract 
Background: Pandemic COVID‑19 caused by the coronavirus SARS‑CoV‑2 has a high incidence of patients with 
severe acute respiratory syndrome (SARS). Many of these patients require admission to an intensive care unit (ICU) for 
invasive ventilation and are at significant risk of developing a secondary, ventilator‑associated pneumonia (VAP).
Objectives: To study the incidence of VAP and bacterial lung microbiome composition of ventilated COVID‑19 and 
non‑COVID‑19 patients.
Methods: In this retrospective observational study, we compared the incidence of VAP and secondary infections 
using a combination of microbial culture and a TaqMan multi‑pathogen array. In addition, we determined the lung 
microbiome composition using 16S RNA analysis in a subset of samples. The study involved 81 COVID‑19 and 144 
non‑COVID‑19 patients receiving invasive ventilation in a single University teaching hospital between March 15th 
2020 and August 30th 2020.
Results: COVID‑19 patients were significantly more likely to develop VAP than patients without COVID (Cox pro‑
portional hazard ratio 2.01 95% CI 1.14–3.54, p = 0.0015) with an incidence density of 28/1000 ventilator days versus 
13/1000 for patients without COVID (p = 0.009). Although the distribution of organisms causing VAP was similar 
between the two groups, and the pulmonary microbiome was similar, we identified 3 cases of invasive aspergillosis 
amongst the patients with COVID‑19 but none in the non‑COVID‑19 cohort. Herpesvirade activation was also numeri‑
cally more frequent amongst patients with COVID‑19.
Conclusion: COVID‑19 is associated with an increased risk of VAP, which is not fully explained by the prolonged dura‑
tion of ventilation. The pulmonary dysbiosis caused by COVID‑19, and the causative organisms of secondary pneumo‑
nia observed are similar to that seen in critically ill patients ventilated for other reasons.
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Background
Pandemic COVID-19 is associated with a high num-
ber of patients suffering from severe acute respiratory 
syndrome (SARS). Such patients can spend significant 
periods of time in intensive care units (ICU), with up 
to 80% of patients admitted to ICU requiring invasive 
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mechanical ventilation [1, 2]. Critically ill patients are 
at high risk of nosocomial pneumonia, especially when 
ventilated [3]. The reasons for this includes breach of 
natural defences by invasive devices [4], sedation and 
impairment of coughing and mucociliary clearance, and 
the immunoparetic effects of critical illness [5, 6]. Early 
reports indicated that critically ill patients infected with 
SARS-CoV-2 had a high prevalence of nosocomial pneu-
monia, especially ventilator-associated pneumonia (VAP) 
[7]. More recent reports, including a large survey from 
a single hospital [8] and a synthesis of the literature [9] 
suggested that rates of secondary infections were low, 
although neither study focussed specifically on critical 
care. There remains considerable uncertainty around the 
incidence of nosocomial infections in severe COVID-19, 
which has led to recent calls for more analysis on the fre-
quency, timing, and causative organisms of these impor-
tant adverse events [10].
Reports of ICU-acquired infection in patients with 
COVID-19 have been limited and have often not 
reported the details of the causative organisms [7], or 
have focused on the incidence of one particular infection 
such as invasive aspergillosis [11]. Importantly, we are 
not aware of reports of ICU-acquired infections compar-
ing patients with COVID-19 and those without managed 
contemporaneously within the same settings, which is 
key to interpreting the frequency, timing, and causative 
organisms leading to these infections.
Ventilator-associated pneumonia (VAP), the common-
est ICU-acquired infection [3], can be challenging to 
diagnose as a range of non-infectious diseases may mimic 
the clinical picture of radiographic infiltrates, systemic 
inflammation and impaired oxygenation that typifies 
VAP [12]. To limit overdiagnosis and facilitate appropri-
ate antimicrobial therapy in VAP, guidelines advocate 
the use of culture- based approaches [13, 14]. However, 
molecular tests to detect multiple pathogens (viruses and 
bacteria) are becoming more accessible and may further 
reduce unnecessary antimicrobial therapy [15] whilst 
enhancing the detection of hard to culture organisms.
During our hospital’s first wave of COVID-19 admis-
sions we noted an apparent increase in the rate of VAP. 
In this study, we therefore aimed to identify and compare 
the distribution of VAP in critically ill ventilated COVID-
19 patients compared to ventilated non-SARS-CoV-2 
infected patients admitted to the same unit. We per-
formed conventional microbiological culture on all lower 
respiratory tract samples. Bronchoalveolar lavage (BAL) 
was also analysed using a multi-pathogen TaqMan array 
card (TAC) we have developed and reported previously 
[16]. In a sub-set of BALs we assessed the composition of 
the bacterial lung microbiome in bronchoalveolar lavage 
(BAL) by 16S sequencing.
Materials and methods
Setting and study design
This study was performed in the liver/general adult 
ICU in Addenbrooke’s Hospital, Cambridge, UK, and 
also included COVID-19 patients managed in the neu-
rotrauma and dedicated COVID-19 ICUs of the hos-
pital. Patients were reviewed at least twice daily by 
consultant intensive care physicians with investigation 
for VAP ordered by this clinician, and discussed at a 
daily microbiology-intensive care multi-disciplinary 
team/antimicrobial stewardship meeting. We had a 
regularly audited ventilator bundle in place, which con-
sisted of sub-glottic suction endotracheal tubes, man-
dated twice daily oral hygiene with fluoride toothpaste, 
daily sedation holds and head of bed elevation. One to 
one nursing to patient ratios were maintained through-
out the first wave of COVID-19, although at times this 
included nurses with limited critical care training as 
normal ICU capacity was exceded. Sessional use of per-
sonal protective equipment (full-length fluid imperme-
able gowns, FFP3 mask, gloves and hat) with apron and 
second glove change between patients was maintained 
from March 15th to July 31st. Patients ventilated for at 
least 48 h, from March 15th (date of our first COVID-
19 admission) to August 30th were retrospectively 
reviewed for presence of VAP. VAP was defined using 
a modification of the European Centre for Disease 
Control definitions [17] for quantitative BAL culture 
(termed PN1) or quantitative endotracheal aspirate 
(ETA) or sputum culture (termed PN2) definitions of 
pneumonia (see Fig. 1). The modifications were to use 
polymerase chain reaction (PCR) positivity by TAC for 
BAL fluid (details below) and to use a threshold of ≥ 105 
Colony Forming Units (CFU)/ml for endotracheal 
aspirate in keeping with UK standards [18]. Low lung 
pathogenicity organisms (Enterococcus spp., Candida 
albicans, non-pneumococcal Streptococci and coagu-
lase negative Staphylococci) were reported but not 
considered a component of VAP [19]. Herpesviridae 
(Herpes simplex, cytomegalovirus and Epstein-Barr 
virus) were reported but were considered to be reacti-
vations and not considered a component of VAP [20].
We also looked for evidence of invasive pulmonary 
aspergillosis (IPA), as there are now several case reports 
of this developing in patients with COVID-19 [11] and 
recent reports of its frequency in non-COVID VAP [21]. 
IPA was defined using the criteria set out in the report 
describing influenza associated pulmonary aspergillosis 
[22] modified to include diagnosis by PCR. The criteria 
were clinical evidence of pulmonary infection, radio-
logical evidence of pulmonary infection and detection of 
aspergillus by BAL galactomannan, PCR positivity or cul-
ture positivity.
Page 3 of 11Maes et al. Crit Care           (2021) 25:25  
Diagnostics
Samples for routine microbiology were processed 
according to the UK Standards for Microbiology Inves-
tigations [18]. Any significant growth with a CFU 
of ≥ 104/mL (on BAL) or ≥ 105/mL ETA was identi-
fied by MALDI-ToF mass spectrometry. Our lab also 
routinely  runs  a multipathogen TaqMan array on 
bronchoalveolar lavage samples [16], the details of this 
are noted below.
TaqMan multi‑pathogen array
Custom designed TaqMan Array Cards (TAC; Thermo 
Fisher Scientific) targeting 52 different common respira-
tory pathogens, were used to test for secondary infections 
as previously described [16]. Detection of a clear expo-
nential amplification curve with a Cycles to Threshold 
(CT) value ≤ 32 for any single gene target was reported as 
a positive result for the relevant pathogen. We have pre-
viously demonstrated that CT value of ≤ 32 corresponded 
to growth ≥ 104/CFU/ml, hence the use of this threshold 
to define VAP [16]. Details of the procedures for extrac-
tion of nucleic acids for TAC, SARS-CoV-2 qPCR and 
16S DNA nanopore sequencing are contained in the sup-
plemental methods.
Statistical analysis
The primary analysis was time to development of first 
VAP, censored for extubation or death, with comparison 
by univariable Cox proportional hazards model. Second-
ary analysis of VAP as an incidence density (cases per 
1000 ventilator days) compared with Mid-P exact test.
Risk factors for VAP were compared using a Cox pro-
portional hazards model, with variables rejected if their 
p value was > 0.05 on univariable analysis, statistically sig-
nificant variables entered the final model. Analyses were 
conducted using SPSS (v25 IBM, Armonk, NY).
Results
Overall, we managed 94 patients with COVID-19, of 
whom 81 were ventilated for more than 48 h. From the 
period 15th March to 30th August we also managed 144 
patients without COVID-19 in the liver/general unit 
who required ventilation for more than 48 h. The demo-
graphic and clinical features of these two groups are 
shown in Table  1 and details of non-COVID admission 
diagnoses in Additional file  1: Table  S1. Ventilator bun-
dle audit data demonstrated high compliance (compli-
ance with the full bundle ranged from 85 to 100%, with 
99–100% for the period April–May when most COVID-
19 patients were admitted).
Patients with COVID-19 were significantly more likely 
to be investigated for VAP (Table  1), and had a higher 
incidence of microbiologically confirmed VAP (39 (48%) 
COVID-19 patients compared to 19 (13%) patients with-
out COVID-19). Further details of the comparison of 
the investigation for VAP are shown in Additional file 1: 
Tables S2 and S3. Patients who were investigated for VAP 
demonstrated a significant deterioration in oxygenation 
VAP case definion – adapted from ECDC17
A combinaon of radiological, clinical and microbiological 
criteria in a paent who has been receiving mechanical 
venlaon for at least 48 hours.
Radiological
New or worsening infiltrates on Chest X-ray or CT thorax
AND
Clinical
AND at least one of the following:
• fever > 38°C with no other cause
• leukopenia (< 4 000 WBC/mm3) or leucocytosis (≥ 
12 000 WBC/mm3).
• and at least one of the following 
o new onset of purulent sputum, or change in 
character of sputum (colour, odour, 
quanty, consistency)
o suggesve auscultaon (rales or bronchial 
breath sounds), rhonchi, wheezing
o worsening gas exchange (e.g. O2
desaturaon or increased oxygen 




Bacteriologic diagnosc performed by:
a) posive quantave culture from minimally 
contaminated LRT specimen (PN 1)
• broncho-alveolar lavage (BAL) with a threshold of ≥ 
104 colony forming units (CFU)/ml 
• detecon by TaqMan array with Ct  ≤ 32
OR
• Posive quantave culture from possibly 
contaminated LRT specimen (PN 2)
• Quantave culture of LRT specimen (e.g. 
endotracheal aspirate) with a threshold of 105
CFU/ml.
Fig. 1 Criteria used for the diagnosis of VAP.  Adapted from the 
European Centre for Disease Control definitions to meet local 
thresholds for quantitative culture of endotracheal aspirate and 
for the inclusion of molecular detection of pathogens. Ct‑cycles to 
threshold by quantitative PCR
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relative to the period immediately prior to the diagnosis 
(Additional file 1: Figure S1).
Survival analysis (Fig.  2) demonstrated that the 
increased risk of developing VAP in patients with 
COVID-19 was not simply a function of longer dura-
tion of ventilation. The hazard of early VAP was similar 
in both groups of patients, however the greater number 
of later VAPs in COVID-19 led to the increased median 
duration of ventilation before VAP developed seen in 
Additional file 1: Table S2. The effect of COVID status on 
VAP-free survival remained significant when adjusted for 
age and immunocompromised status (adjusted p value 
0.045 by Cox proportional hazards model, Additional 
file 1: Table S5). Sensitivity analysis of patients with > 72 h 
mechanical ventilation and > 144  h of mechanical ven-
tilation produced similar survival curves and hazard 
ratios (Additional file  1: Figure S2A and B). A similar 
finding was apparent when comparing crude incident 
density, patients with COVID-19 developed VAP at a 
rate of 28/1000 ventilator days, whilst those without 
COVID-19 experienced VAP at a rate of 13/1000 ventila-
tor days (p = 0.009 by mid-P exact test). Incident density 
censoring for post-VAP duration ventilation, which is 
confounded by VAP itself prolonging ventilation, shows 
a similar pattern (40/1000 ventilator days for COVID-
19, 19/1000 ventilator days for non-COVID p = 0.004 by 
mid-P exact test). Further details on timing of VAP are 
available in the supplemental section (Additional file  1: 
Table  S2). Antibiotic use on admission (Table  1) and in 
the period leading up to investigation for suspected VAP 
(Additional file  1: Tables S3 and S4) was similar in fre-
quency and spectrum of agents used.
The organisms identified on endotracheal aspirate 
culture and both culture and molecular testing of bron-
choalveolar lavage fluid are show in Table  2. The con-
cordance between culture and molecular testing was 
high, although molecular testing identified a number of 
additional organisms.
The distribution of organisms in COVID-19 and non-
COVID-19 associated VAP is shown in Fig.  3, and is 
broadly similar between both groups.
Table 1 Clinical and demographic features of reported populations
P value by z-test for proportions and by Mann–Whitney U test for continuous variables
* Immunocompromised patients were defined as having active haematological malignancy, neutropaenic malignancy, solid organ or bone marrow transplant and 
receipt of immunosuppressive medication including corticosteroids for > 1 week prior to hospital admission
# 4 cases not assessed by TAC due to lack of availability of laboratory capacity
## 1 case not assessed by TAC due to lack of availability of laboratory capacity
APACHE II, Acute physiology and chronic health evaluation II score; IQR, interquartile range
Parameter COVID‑19 (n = 81) Non‑COVID‑19 (n = 144) P value
Median age (IQR) 62 (50–70) 62 (49–72) 0.986
Sex (n (%) female) 25 (31%) 58 (40%) 0.254
Hypertension 27 (33%) 47 (33%) 0.96
Diabetes 18 (22%) 34 (24%) 0.72
Obesity 30 (37%) 34 (24%) 0.04
Chronic kidney disease 10 (12%) 13 (9%) 0.47
Chronic lung disease 16 (20%) 34 (24%) 0.38
Immunocompromised* 12 (15%) 36 (25%) 0.08
Corticosteroid use in ICU 13 (16%) 23 (16%) 0.99
Median APACHE II (IQR) 15 (11–19) 16 (12–20) 0.06
% With ARDS on ICU admission 63 (78%) 21 (15%)  < 0.0001
% Ventilated prone 40 (49%) 1 (0.7%)  < 0.0001
Median P/F ratio in 24 h following admission 18 (13–28) 34 (24–37)  < 0.0001
Antibiotics in 24 h following admission 76 (94%) 126 (88%) 0.23
Median ICU length of stay (IQR) 15 (11–25) 9 (4–13)  < 0.0001
Median duration of ventilation (IQR) 14 (10–23) 5 (2–11)  < 0.0001
% Developing suspected VAP 64 (79%) 48 (33%)  < 0.0001
% Developing microbiologically confirmed VAP 39 (48%) 19 (13%)  < 0.0001
% of suspected VAPs investigated by bronchoscopy and lavage 30 (47%#) 23 (48%##) 0.94
ICU mortality 31 (38%) 30 (21%) 0.006
Median length of stay for patients dying in ICU (IQR) 13 (10–17) 9 (6–11) 0.0019
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Lung microbiota
To investigate changes in the lung microbiota in the 
COVID-19 positive and negative patients we per-
formed 16S rRNA sequencing on a subset of BAL sam-
ples from 24 patients. In general, bacteria detected by 
TAC or conventional microbiology were abundantly 
identified in samples by 16S sequencing (Fig.  4). Sam-
ples with confirmed VAP or colonization with low 
pathogenic organisms generally yielded higher overall 
read numbers. When comparing COVID-19 positive 
to COVID-19 negative patients, there was no specific 
taxon that was more prevalent in either group. Addi-
tionally, in this relatively small subset of samples, the 
bacterial composition of BALs from COVID-19 posi-
tive patients were not significantly different in either 
the species richness (alpha diversity) or the microbial 
composition (beta diversity).
To investigate changes in the microbiota over the 
course of infection, we next looked at the microbial com-
position of BAL samples in some individual patients over 
time. Two patients diagnosed with VAP (patients 1 and 
24) showed decreasing species richness over time, as 
the bacterial pathogen implicated in the illness became 
the predominant microbe present. For patient 6, the 
microbial composition shifted significantly over time, as 
Enterococcus took over from Staphylococcus as the most 
predominant organism. The microbiome composition of 
patient 24, who was both VAP and COVID-19 negative, 
was largely stable over time. In general, the microbial 
composition of BAL samples from patients who did not 
have VAP at the time of sampling (sample 1 from patient 
14 and both samples from patient 24) were more diverse 
than samples from patients who had been diagnosed with 
VAP.
Invasive aspergillosis
43 patients were investigated for possible pulmonary 
aspergillosis by PCR and lavage galactomannan, on the 
basis of senior clinician suspicion of fungal infection. 
23 patients with COVID-19 and 20 without. Of these 3 
COVID-19 patients met the criteria for IPA outlined in 
the methods above (one positive by PCR with border-
line galactomannan 0.7 optical density index (ODI), and 
2 PCR negative but with galactomannan > 1.0 ODI), and 
all were treated with liposomal amphotericin, 2 of these 
patients survived to hospital discharge whilst one died. 
One patient without COVID-19 had a borderline posi-
tive galactomannan (0.8 ODI), and met clinical crite-
ria but was not treated as care was withdrawn for other 
reasons. We estimate the prevalence of COVID-19-as-
sociated aspergillosis (CAPA) to be 13%, although with 
small numbers the confidence intervals are wide (95% 
CI 5–32%). None of the three patients with CAPA had 
received steroids prior to the diagnosis.
Fig. 2 Time to development of VAP in patients with and without COVID‑19 censored for death or extubation. P value and hazard ratio by Cox 
proportional hazards. Numbers at risk at each time point indicated below x‑axis
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Table 2 Organisms identified by culture and PCR testing (BAL only) in patients with confirmed VAP
* Sequence for the organism in question not present on the TAC 
! 1 E. coli was detected by culture but not TAC in a patient, 2 E. coli detected by TAC without growth on culture









Citrobacter freundii 1 *
Citrobacter koseri 1 1 *
Coliform (not further specified) 1
Escherichia coli 5 3! 4!
Enterobacter asburiae 1 *
Enterobacter cloacae 3
Enterobacteraeciae (not further specified) 2
Haemophilus influenzae 1 4
Klebsiella aerogenes 2 1 *
Klebsiella pneumoniae 2 3 5
Klebsiella oxytoca 3 1 *
Proteus mirabilus 1 1$
Pseudomonas aeruginosa 7 3 2
Serratia liquefaciens 1
Serratia marcescens 1 2 5
Stenotrophomonas maltophilia 3 4 4
Gram positive




Candida albicans 6 4 4
Candida spp. 1
Coagulase negative Staphylococci 1 4
Enterococcus faecium 2 7
Streptococcus spp. (non‑pneumoniae, non‑pyogenes) 4
Herpes simplex virus 2
Fig. 3 Causative organisms of VAP in patients with and without COVID‑19. Non‑pathogenic organisms detected above threshold levels shown in 
grey
Page 7 of 11Maes et al. Crit Care           (2021) 25:25  
Reactivation of herpesvirade
49 patients had lavage tested for herpesvirade, 24 with 
COVID-19 and 25 without. Although five patients (two 
with VAP from other organisms, and three without VAP) 
had detection of herpes simplex virus (HSV) below the 
Ct cut-off of 32, in viral reactivation the role of viral load 
is uncertain. We therefore examined the frequency of 
herpesvirade detection at any level in lavage of patients 
investigated for suspected VAP. In total 10 patients with 
COVID-19 had detection of herpesvirade (4 HSV, 5 
Epstein barr virus (EBV) and 1 patient with both), whilst 
5 patients without COVID-19 had detection (2 HSV, 1 
cytomegalovirus, 1 EBV and 1 patient with both HSV 
and EBV). As only lavage was tested for herpesvirade, the 
prevalence of herpesvirade detection amongst the tested 
population was 42% (95% CI 24–61%) in patients with 
COVID-19 and 20% (95% CI 9–39%) in patients without 
COVID-19 (distribution of Ct values for herpesvirade are 
shown in Additional file 1: Figure S3). Only one patient 
with herpesvirade activation had received steroids prior 
to detection.
Discussion
COVID-19 is a new disease in the human population and 
this has led to an increase in the number of patients in 
need of mechanical ventilation, which in turn introduces 
the risk of VAP. COVID-19 can present in various severe 
manifestations and reports of co-infections vary [7–9]. 
However, often these reports suffer from a lack of clar-
ity around the severity of illness, location of patients 
(critical care vs non-critical care), timing of sampling 
relative to onset of disease and, where applicable, the use 
of mechanical ventilation. Here, we report on the most 
severely affected COVID-19 patients who required ICU 
admission with mechanical ventilation. We found that 
relative to patients without COVID-19, the hazard of 
VAP was significantly elevated.
Conventional surveillance for VAP uses incidence den-
sity, which we calculated to allow comparison with pre-
viously published reports. We found a high incidence 
density of confirmed VAP (28/1000 ventilator days) 
amongst patients with COVID-19, whilst those without 
COVID-19 had rates closer to those reported from other 
Patient 24 Patient 1 Patient 6 Patient 14





















































Fig. 4 Microbial composition of BAL samples from SARS‑CoV‑2 positive and negative patients. Bacterial 16S genes were sequenced and classified 
to the genus level using Kraken2. The number and percent of reads mapping to each genus is shown for individual samples from each patient 
(A), with kit controls in the first two columns, and longitudinal samples (1, 2 or 3) from individual patients (B). Individuals were classified as either 
COVID‑19 negative, COVID‑19 positive, or recovering (previously diagnosed with COVID‑19 but SARS‑CoV‑2 negative at time of sample)
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units in the pre-COVID-19 era, where incident densities 
were 6–14/1000 ventilator days for confirmed VAP were 
reported [23]. As sessional use of personal protective 
equipment remained in place until the end of July 2020, 
for management of both COVID-19 and non-COVID-19 
patients, we do not think that this influenced the differ-
ential acquisition of VAP amongst these two groups.
The distribution of infecting organism was similar 
between patients with and without COVID-19, and 
reflects that reported in the literature from previous 
surveys of ICU-acquired infections from before the 
COVID era [3, 19]. The use of the TAC allowed more 
rapid identification of organisms, most of which were 
subsequently identified by culture. Notably there were a 
few organisms the TAC did not detect, largely because 
sequences for these organisms were not present on the 
card, these were distributed between both the COVID-
19 and non-COVID patients.
At the lung microbiome level, we observed no differ-
ence in the composition of organisms between COVID-
19 positive and non-COVID patients who developed 
VAP. Reassuringly, antibiotic susceptibility of the caus-
ative pathogens was similar in the two groups (data not 
shown) and this meant that conventional antimicrobial 
regimens could be used.
There is increasing recognition of fungal infec-
tions amongst patients with viral pneumonitides and 
VAP [11, 21, 22]. Although debate continues regard-
ing the differences and similarities between influenza 
and COVID-associated aspergillosis [10], in keeping 
with our findings in bacterial VAP it appears that IPA 
is more common in COVID-19 patients than in ICU 
patients without COVID-19. It has been suggested that 
CAPA may relate to the use of immunosuppressive 
medications [10]. As can be seen from Table 1, steroids 
were relatively rarely used in this cohort of COVID-19 
patients who were largely admitted before the results 
of the RECOVERY trial had been announced [24] and 
indeed none of the 3 CAPA patients we identified had 
received steroids prior to their diagnosis or had under-
lying immunosuppressive conditions.
More broadly, in our setting immunomodulatory 
medications were not commonly used at the time of the 
peak of the COVID-19 admissions, yet there remains 
a high prevalence of bacterial VAP in these patients. 
Although VAP in COVID-19 may present problems 
of quantity, we did not find evidence in this report of 
a qualitative difference in terms of the organisms caus-
ing infection, although as noted above aspergillosis may 
be more common although this needs to be seen in the 
context of a significantly higher rate of VAP overall. 
In the subset where we undertook microbiome profil-
ing, our patients demonstrated similar profiles to those 
reported by other groups investigating the pulmonary 
microbiome of ventilated patients [25, 26]. The fac-
tors which lead to pulmonary dysbiosis in critical ill-
ness remain incompletely understood, but may include 
intercurrent antibiotic use, enteric translocation, pul-
monary immune dysfunction and altered clearance 
[27].
Although patients without COVID-19 developed pro-
portionately more ‘early’ VAP, being VAP within the first 
4 days of ventilation (Additional file 1: Table S2), exami-
nation of the VAP-free survival curves (Fig. 2) reveals the 
hazard of early VAP is similar between the two groups. 
What is striking, however, is the ongoing risk of VAP 
seen in patients with COVID-19 which is greater than 
that seen in patients without COVID. This ongoing risk is 
reminiscent of the effect we reported previously in criti-
cally ill patients with marked immunoparesis [5].
Although from our observational study we cannot 
be certain why ventilated patients with COVID-19 
have such a significantly increased risk of infection, 
previous work has indicated that the strongest predic-
tor of nosocomial infection in critically ill patients is 
impaired immune cell function [5, 28]. Patients with 
COVID-19, in keeping with other critical illness syn-
dromes such as bacterial sepsis and major trauma, 
experience a complex dysregulation of their immune 
function with features of both hyperinflammatory 
activation and organ damage as well as impaired 
antimicrobial functions [6, 29]. Notably, one of the 
key drivers of neutrophil impairment in critical ill-
ness is the complement component C5a [30, 31] and 
high levels of complement activation and C5a release 
have been reported in COVID-19 [32]. Other recent 
reports on the immunology of COVID-19 highlight 
marked increases in markers of immune cell func-
tional suppression in the most severely unwell patients 
[29]. Damage to the alveolar membrane, although not 
specific to COVID-19, may also facilitate invasion 
of bacterial species [33]. The estimates of the preva-
lence of invasive pulmonary aspergillosis and her-
pesvirade reactivation are limited to those patients 
investigated by broncho-alveolar lavage and therefore 
represent only a subset of those investigated for VAP. 
In the case of invasive aspergillosis it also required 
senior clinician ordering of galactomannan, and as 
a retrospective study we cannot be sure clinicians 
had a common threshold for requesting this test. We 
therefore acknowledge that these data may underesti-
mate the prevalence of these conditions, however the 
trend towards higher prevalence amongst patients 
with COVID-19 adds some support to the hypothesis 
that these patients suffer from a considerable bur-
den of immunoparesis. It is notable, if not surprising, 
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that patients with COVID-19 were much more likely 
to present with acute respiratory distress syndrome 
(ARDS) (Table  1) and consequently had more severe 
oxygenation defects and were much more likely to be 
ventilated prone. ARDS is an established risk factor 
for VAP [34], and the intense pulmonary inflammation 
can lead to immunologic reprogramming which can 
impair anti-microbial responses [35]. Prone position-
ing may increase risk of microaspiration, however dis-
secting out the specific effects of proning as opposed 
to the severity of the underlying lung inflammation 
remains challenging [36]. Whilst previous broad-
spectrum antimicrobial therapy is an acknowledged 
risk factor for VAP [15] we did not find evidence of 
substantial differences in either antibmicrobial use or 
spectrum in patients with and without COVID19.
VAP remains difficult to definitively confirm without 
histological confirmation, which is seldom practical 
nor desirable in ventilated patients, we therefore can-
not be certain that the patients with positive micro-
biology had definite pneumonia, although the use of 
quantitative cultures reduces the risk of detection of 
colonisation as opposed to infection [17, 37]. We used 
a clinically relevant definition similar to that used in 
previous studies [17, 37] and applied this consistently 
across the two groups. We note that diagnostic tech-
nique can alter the rate of diagnosis [37], and therefore 
think it is reassuring that the proportion of broncho-
scopic diagnoses was consistent across both groups 
(Table 1). Similarly, the use of the more sensitive TAC 
molecular diagnostic could increase the apparent rate 
of microbiologically confirmed VAP, it is reassuring 
that TAC was used marginally more frequently in the 
non-COVID patients and this also suggests the dif-
ference seen is due to biological rather than technical 
reasons.
Reports of rates of VAP amongst ventilated patients 
with COVID-19 vary, with rates of 40–86% reported 
[38–40] and our reported rate of 49% is in keeping with 
reports from other centres. Although some reports, not 
focussed specifically on VAP, indicate lower rates of 
10% [8], it is unclear how many of the ICU patients in 
that cohort were ventilated for at least 48 h. The rates 
of VAP between centres managing COVID-19 are likely 
to vary depending on the clinical characteristics of the 
patients managed, differential ICU admissions policies 
and clinical factors such as use of immunosuppressive 
therapies. Although we managed to maintain one to 
one nursing ratios throughout the first wave of COVID-
19, it is possible that the increased numbers of nurses 
with only brief training in critical care led to increased 
rates of VAP. However, the continued high compliance 
with the ventilator care bundle which includes key 
nursing interventions such as oral hygiene and head of 
bed elevation argues against this being a major factor. 
We acknowledge the sample size and single centre limi-
tations with our observations and suggest larger stud-
ies from distinct geographic locations may help fully 
understand the risk of developing secondary bacterial 
infections in patients with severe COVID-19.
Conclusion
COVID-19 makes people more susceptible to developing 
VAP, partly but not entirely due to the increased dura-
tion of ventilation. The change in lung microbiome and 
causes of secondary infection are similar to those seen in 
critically ill patients ventilated for other reasons. Care-
ful sampling of the respiratory tract whilst minimising 
contamination from the proximal tract, in combination 
with sensitive diagnostic testing to reduce the risk of false 
negative cultures will aid antimicrobial optimisation in 
patients with COVID-19.
Supplementary information
Supplementary information accompanies this paper at https ://doi.
org/10.1186/s1305 4‑021‑03460 ‑5.
Additional file 1. Supplemental methods and results.
Acknowledgements
Our thanks go out to all the ICU clinicians, nurses and physiotherapists who 
have ensured proper patient care and sample management even in these 
hard times, as well as to PHE microbiologists for running standard microbiol‑
ogy tests. Furthermore, the authors wish to thank Mark Wills for his help as Bio‑
logical Safety Officer to ensure we work in a safe environment. We also thank 
M Estée Török and Ian Goodfellow for access to consumables and the GridION 
for Nanopore sequencing, and Satpal Ubhi for help with clinical data collec‑
tion. Finally, we wish to acknowledge our funders the NIHR BRC. In addition 
we would like to acknowledge the grant awarded by Addenbrooke’s Charita‑
ble Trust for the initial study of the clinical utility of the TaqMan microarray [16].
Authors’ contributions
MM: sample processing, data analysis and manuscript writing; EEH: sample 
processing, data analysis and manuscript editing; JPD, DCL, JL, AS, SF,SS: sam‑
ple processing and manuscript editing; FK: sample processing, data analysis 
and manuscript editing; SSH, BR, LH, IM, RM: clinical data collection and manu‑
script editing; MDC, SP, NB: diagnostic data analysis and manuscript editing; 
SB: supervision of laboratory assays and manuscript editing; VN: conceived 
study and sample acquisition: GD: conceived study, supervision of laboratory 
assays and manuscript editing; JBS: conceived study, sample processing and 
manuscript editing; ACM: conceived study, manuscript writing, sample acqui‑
sition, data analysis and clinical data collection. All authors read and approved 
the final manuscript.
Funding
This study was funded by the National Institute for Health Research [Cam‑
bridge Biomedical Research Centre at the Cambridge University Hospitals NHS 
Foundation Trust, AMR theme]. The views expressed are those of the authors 
and not necessarily those of the NHS, the NIHR or the Department of Health 
and Social Care. Dr Conway Morris is supported by a Clinical Research Career 
Development Fellowship from the Wellcome Trust (WT 2055214/Z/16/Z).
Availability of data and materials
Raw sequencing data has been deposited at https ://www.ncbi.nlm.nih.gov/
biopr oject /PRJNA 64201 2.
Page 10 of 11Maes et al. Crit Care           (2021) 25:25 
Ethical approval and consent to participate
The TaqMan multi-pathogen array has been adopted as a routine clinical 
service in our institution following a previous evaluation study [16]. The use of 
discard samples surplus to that required for clinical testing, and anonymised 
data review were conducted under the consent waiver granted by Leeds West 
NHS Research Ethics Committee (ref: 20/YH/0152).
Consent for publication
All authors read and approved the final version for publication.
Competing interests
The authors have declared that no competing interests exist.
Author details
1 Department of Medicine, Cambridge Institute of Therapeutic Immunol‑
ogy and Infectious Disease (CITIID), University of Cambridge, Cambridge, UK. 
2 Public Health England, Clinical Microbiology and Public Health Laboratory, 
Addenbrooke’s Hospital, Cambridge, UK. 3 Division of Anaesthesia, Depart‑
ment of Medicine, University of Cambridge, Level 4, Addenbrooke’s Hospital, 
Hills Road, Cambridge CB2 0QQ, UK. 4 John Farman ICU, Addenbrookes Hospi‑
tal, Cambridge, UK. 5 Wellcome Sanger Institute, Hinxton, UK. 
Received: 7 October 2020   Accepted: 4 January 2021
References
 1. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of covid‑19 in 
New York City. N Engl J Med. 2020;382:2372–4.
 2. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and 
outcomes of 1591 patients infected with SARS‑CoV‑2 admitted to ICUs 
of the Lombardy Region, Italy. JAMA. 2020;323:1574–8.
 3. Vincent J‑L, Sakr Y, Singer M, et al. Prevalence and outcomes of 
infection among patients in intensive care units in 2017. JAMA. 
2020;323:1478–510.
 4. Álvarez‑Lerma F, Palomar‑Martínez M, Sánchez‑García M, et al. 
Prevention of ventilator‑associated pneumonia. Crit Care Med. 
2018;46(2):181–8.
 5. Morris AC, Datta D, Shankar‑Hari M, et al. Cell‑surface signatures of 
immune dysfunction risk‑stratify critically ill patients: INFECT study. 
Intensive Care Med. 2018;44:627–35.
 6. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a 
novel understanding of the disorder and a new therapeutic approach. 
Lancet Infect Dis. 2013;13:260–8.
 7. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of 
adult inpatients with COVID‑19 in Wuhan, China: a retrospective cohort 
study. Lancet. 2020;395:1054–62.
 8. Garcia‑Vidal C, Sanjuan G, Moreno‑García E, et al. Incidence of co‑
infections and superinfections in hospitalized patients with COVID‑19: 
a retrospective cohort study. Clin Microbiol Infect. 2020;27:83–8.
 9. Rawson TM, Moore LSP, Zhu N, et al. Bacterial and fungal co‑infection 
in individuals with coronavirus: a rapid review to support COVID‑19 
antimicrobial prescribing. Clin Infect Dis. 2020. https ://doi.org/10.1093/
cid/ciaa5 30.
 10. Bassetti M, Kollef MH, Timsit J‑F. Bacterial and fungal superinfec‑
tions in critically ill patients with COVID‑19. Intensive Care Med. 
2020;12(2):e0187791.
 11. van Arkel ALE, Rijpstra TA, Belderbos HNA, van Wijngaarden P, Verweij 
PE, Bentvelsen RG. COVID‑19‑associated pulmonary aspergillosis. Am J 
Respir Crit Care Med. 2020;202:132–5.
 12. Meduri GU, Mauldin GL, Wunderink RG, et al. Causes of fever and pul‑
monary densities in patients with clinical manifestations of ventilator‑
associated pneumonia. Chest. 1994;106:221–35.
 13. Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/
ESCMID/ALAT guidelines for the management of hospital‑acquired 
pneumonia and ventilator‑associated pneumonia: Guidelines for the 
management of hospital‑acquired pneumonia (HAP)/ventilator‑associ‑
ated pneumonia (VAP) of the European Respiratory Society (ERS), Euro‑
pean Society of Intensive Care Medicine (ESICM), European Society of 
Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación 
Latinoamericana del Tórax (ALAT). Eur Respir J. 2017;50(3):1700582.
 14. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with 
hospital‑acquired and ventilator‑associated pneumonia: 2016 clinical 
practice guidelines by the infectious diseases Society of America and 
the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61–111.
 15. Arulkumaran N, Routledge M, Schlebusch S, Lipman J, Conway MA. 
Antimicrobial‑associated harm in critical care: a narrative review. Inten‑
sive Care Med. 2020;46:225–35.
 16. Navapurkar V, Bartholdson‑Scott J, Maes M, et al. Development 
and implementation of a customised rapid syndromic diagnos‑
tic test for severe pneumonia. medRxiv. 2020. 1–21. https ://doi.
org/10.1101/2020.06.02.20118 489.
 17. Plachouras D, Lepape A, Suetens C. ECDC definitions and methods for 
the surveillance of healthcare‑associated infections in intensive care 
units. Intensive Care Med. 2018;44(12):2216–8.
 18. SMI B 57: investigation of bronchoalveolar lavage, sputum and associ‑
ated specimens. https ://www.gov.uk/gover nment /publi catio ns/smi‑
b‑57‑inves tigat ion‑of‑bronc hoalv eolar ‑lavag e‑sputu m‑and‑assoc iated 
‑speci mens. Accessed 25 Sept 2020.
 19. Chastre J, Fagon J‑Y. Ventilator‑associated pneumonia. Am J Respir Crit 
Care Med. 2002;165(7):867–903.
 20. Bruynseels P, Jorens PG, Demey HE, et al. Herpes simplex virus in the 
respiratory tract of critical care patients: a prospective study. Lancet. 
2014;362(9395):1–6.
 21. Loughlin L, Hellyer TP, White PL, et al. Pulmonary aspergillosis in 
patients with suspected ventilator‑associated pneumonia in UK Inten‑
sive Care Units. Am J Respir Crit Care Med. 2020;202:1125–32.
 22. Schauwvlieghe AFAD, Rijnders BJA, Philips N, et al. Invasive aspergillosis 
in patients admitted to the intensive care unit with severe influenza: a 
retrospective cohort study. Lancet Respir Med. 2018;6(10):782–92.
 23. Morris AC, Hay AW, Swann DG, et al. Reducing ventilator‑associated 
pneumonia in intensive care: Impact of implementing a care bundle. 
Crit Care Med. 2011;39(10):2218–24.
 24. Horby P, Lim WS, RECOVERY Collaborative Group, et al. Dexamethasone 
in hospitalized patients with covid‑19‑preliminary report. N Engl J Med. 
2020. https ://doi.org/10.1056/NEJMo a2021 436.
 25. Zakharkina T, Martin‑Loeches I, Matamoros S, et al. The dynamics of the 
pulmonary microbiome during mechanical ventilation in the intensive 
care unit and the association with occurrence of pneumonia. Thorax. 
2017;72(9):803–10.
 26. Dickson RP, Singer BH, Newstead MW, et al. Enrichment of the lung 
microbiome with gut bacteria in sepsis and the acute respiratory 
distress syndrome. Nat Microbiol. 2016;1(10):16113.
 27. Roquilly A, Torres A, Villadangos JA, et al. Pathophysiological role of 
respiratory dysbiosis in hospital‑acquired pneumonia. Lancet Respir 
Med. 2019;7(8):710–20.
 28. Conway Morris A, Anderson N, Brittan M, et al. Combined dysfunctions 
of immune cells predict nosocomial infection in critically ill patients. Br 
J Anaes. 2013;111(5):778–87.
 29. Laing AG, Lorenc A, del Molino del Barrio I, et al. A dynamic COVID‑19 
immune signature includes associations with poor prognosis. Nat Med. 
2020;26:1623–35.
 30. Wood AJ, Vassallo AM, Ruchaud‑Sparagano M‑H, et al. C5a impairs 
phagosomal maturation in the neutrophil through phosphoproteomic 
remodeling. JCI Insight. 2020;5(15):93.
 31. Morris AC, Brittan M, Wilkinson TS, et al. C5a‑mediated neutrophil 
dysfunction is RhoA‑dependent and predicts infection in critically ill 
patients. Blood. 2011;117(19):5178–88.
 32. Carvelli J, Demaria O, Vély F, et al. Association of COVID‑19 inflamma‑
tion with activation of the C5a–C5aR1 axis. Nature. 2020;4:1–5.
 33. Mason RJ. Pathogenesis of COVID‑19 from a cell biology perspective. 
Eur Respir J. 2020;55(4):2000607.
 34. Luyt C‑E, Bouadma L, Morris AC, et al. Pulmonary infections complicat‑
ing ARDS. Intensive Care Med. 2020;46(12):2168–83.
 35. Roquilly A, McWilliam HEG, Jacqueline C, et al. Local modulation of 
antigen‑presenting cell development after resolution of pneumonia 
induces long‑term susceptibility to secondary infections. Immunity. 
2017;47(1):135‑147.e135.
Page 11 of 11Maes et al. Crit Care           (2021) 25:25  
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 36. Ayzac L, Girard R, Baboi L, et al. Ventilator‑associated pneumonia in 
ARDS patients: the impact of prone positioning. A secondary analysis 
of the PROSEVA trial. Intensive Care Med. 2015;42(5):871–8.
 37. Morris AC, Kefala K, Simpson AJ, et al. Evaluation of the effect of diag‑
nostic methodology on the reported incidence of ventilator‑associated 
pneumonia. Thorax. 2009;64(6):516–22.
 38. Cheng K, He M, Shu Q, Wu M, Chen C, Xue Y. Analysis of the risk fac‑
tors for nosocomial bacterial infection in patients with COVID‑19 in a 
Tertiary Hospital. Risk Manag Healthc Policy. 2020;13:2593–9.
 39. Schmidt M, Hajage D, Demoule A, et al. Clinical characteristics and day‑
90 outcomes of 4244 critically ill adults with COVID‑19: a prospective 
cohort study. Intensive Care Med. 2020;47:60–73.
 40. Luyt C‑E, Sahnoun T, Gautier M, et al. Ventilator‑associated pneumonia in 
patients with SARS‑CoV‑2‑associated acute respiratory distress syndrome 
requiring ECMO: a retrospective cohort study. Ann Intensive Care. 
2020;10:158.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
